Austin, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Non-Viral Gene Delivery Technologies Market Size & Growth Analysis:
According to SNS Insider estimates, the Non-Viral Gene Delivery Technologies Market size was valued at USD 3.73 billion in 2025 (Estimated) and is expected to reach USD 9.57 billion by 2033, growing at a CAGR of 12.55% over the forecast period of 2026–2033.
The increasing focus on gene editing, RNA-based therapies, and personalized medicine is significantly contributing to market expansion. The Non-viral gene delivery systems such as lipid nanoparticles, polymer-based carriers, electroporation, and physical delivery methods are gaining traction due to their improved safety profiles, lower immunogenicity, scalable manufacturing, and flexibility in payload design compared to viral vectors.
Get a Sample Report of Non-Viral Gene Delivery Technologies Market: https://www.snsinsider.com/sample-request/8166
These technologies are increasingly utilized in applications including cancer therapy, genetic disorders, vaccine development, and regenerative medicine. Rising investments in biotechnology R&D, expanding clinical pipelines, and favorable regulatory support for advanced therapies are further accelerating the adoption of non-viral gene delivery platforms.
U.S. Market Insights:
The U.S. non-viral gene delivery technologies market size was valued at USD 1.15 billion in 2025 and is projected to reach USD 2.91 billion by 2033, expanding at a CAGR of 12.32% over the forecast period of 2026–2033. The U.S. remains a dominant contributor to global market growth due to its strong biotechnology ecosystem, high concentration of gene therapy developers, and substantial funding for genomic and molecular research. Increased clinical trial activity, early adoption of lipid nanoparticle-based delivery systems, and growing collaboration between academic institutions and biopharmaceutical companies are key factors supporting market expansion in the country.
Major Players Analysis Listed in the Non-Viral Gene Delivery Technologies Market Report are
- Polyplus-transfection SA
- Mirus Bio LLC
- Altogen Biosystems
- SignaGen Laboratories
- OZ Biosciences
- MaxCyte Inc.
- IBA GmbH
- Thermo Fisher Scientific
- Merck KGaA
- QIAGEN N.V.
- Takara Bio Inc.
- Biontex Laboratories GmbH
- Promega Corporation
- Bio-Rad Laboratories Inc.
- GenScript Biotech Corporation
- Lonza Group AG
- Agilent Technologies Inc.
- EMD Millipore
- OriGene Technologies Inc.
- Bio-Techne Corporation
- and other players
Non-Viral Gene Delivery Technologies Market Report Scope
| Report Attributes | Details |
| Market Size in 2025E | USD 3.73 billion |
| Market Size by 2033 | USD 9.57 billion |
| CAGR | CAGR of 12.55 % From 2025 to 2032 |
| Base Year | 2025 |
| Forecast Period | 2026-2033 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Segmentation Analysis:
By Mode
The physical segment showed a significant share of the non-viral gene delivery technologies market in 2024, owing to the effectiveness of direct gene transfer along with the high efficiency associated with incorporation in the target cell, with less risk of immunogenicity. The chemical segment is anticipated to grow at the fastest rate during the forecast period, owing to the rapid development of nanotechnology and the design of novel chemical vectors that are more efficient and less toxic.
By Application
The research segment dominated the non-viral gene delivery technologies market share with around 69.2% in 2024 due to the high use of gene delivery tools in academic and preclinical research. Due to increased general interest in gene-based therapies directed towards chronic and genetic diseases such as cancer and rare diseases, the therapeutics segment is expected to grow the fastest over the forecast period.
By Method
The ex vivo segment held the largest share by method of non-viral gene delivery technologies market in 2024, attributed to the better-controlled environment and higher efficiency in gene modification as compared to in vivo. The In Vivo segment is expected to witness substantial growth across the forecast years owing to its scope of direct and relatively less invasive therapeutic applications.
By End-Use
By end-use, the non-viral gene delivery technologies market share was led by the research and academic institutes segment in 2024, with around 45.6% due to significant utilization of non-viral gene delivery techniques in fundamental research, specifically in areas concerning investigations of gene roles, cell biology, and diseases with cellular genetic components. The biotechnology and biopharmaceutical company segment is expected to show significant growth, owing to the growing usage of L-glutamine during the forecast period.
Need Any Customization Research on Non-Viral Gene Delivery Technologies Market, Enquire Now: https://www.snsinsider.com/enquiry/8166
Key Non-Viral Gene Delivery Technologies Market Segments
By Mode
- Chemical
- LNPs
- Polymers
- Others
- Physical
- Electroporation
- Microinjection
- Others
By Application
- Research
- Therapeutics
- Gene Therapy
- Cell Therapy
- Vaccines
By Method
- Ex Vivo
- In Vivo
- In Vitro
By End Use
- Biotechnology and Biopharmaceutical Companies
- Research and Academic Institutes
- Others
Regional Insights:
North America is the dominating region due to the advanced research infrastructure, high healthcare spending, and a strong presence of key biotech and pharmaceutical companies in the non-viral gene delivery technologies market, with around 40% in 2024.
The significant growth of the non-viral gene delivery technologies market in Asia Pacific is attributed to the rising investments in biotechnology, improving the healthcare infrastructure, and significant emphasis on precision medicine.
Recent Developments:
- March 2024 – Sartorius has added to its plasmid offering with the introduction of RPLUS, AAV-RC2, a Bercar plasmid for the manufacture of adeno-associated virus vector 2 (AAV2) that extends the company's ability to respond to a wider number of AAV serotypes, enabling more advanced gene therapy applications.
- September 2024 – ProBio and UCI Therapeutics entered into a strategic memorandum of understanding (MOU) with the goal of developing NK cell gene introduction technologies. The MOU envisions a commitment to work together to develop both viral and non-viral gene delivery technologies, enhancing cell and gene therapy innovation.
Purchase Single User PDF of Non-Viral Gene Delivery Technologies Market Report (20% Discount): https://www.snsinsider.com/checkout/8166
Exclusive Sections of the Report (The USPs):
- DISEASE BURDEN & THERAPEUTIC DEMAND METRICS – helps you understand demand fundamentals by analyzing the prevalence of genetic disorders, incidence of chronic diseases, rising cancer and rare disease cases, and regional distribution of target patient populations.
- RESEARCH ACTIVITY & CLINICAL PIPELINE INDICATORS – helps you gauge innovation momentum by tracking the number of preclinical and clinical trials, regional research output, funding trends from governments and academia, and the formation of institutional collaboration hubs.
- TECHNOLOGY ADOPTION & VOLUME GROWTH TRENDS – helps you identify commercialization potential by comparing non-viral versus viral vector usage, annual adoption volumes, application split between research and therapeutics, and growth across ex vivo, in vivo, and in vitro delivery methods.
- HEALTHCARE & R&D SPENDING BENCHMARKS – helps you evaluate investment support by analyzing regional healthcare expenditure, private and biotech funding inflows, and patient out-of-pocket spending on gene-based therapeutics.
- REGIONAL MARKET OPPORTUNITY & SCALABILITY INSIGHTS – helps you assess geographic growth hotspots by linking disease burden, research intensity, technology uptake, and funding availability across North America, Europe, Asia Pacific, and other regions.
Access Complete Report Details of Non-Viral Gene Delivery Technologies Market Analysis & Outlook: https://www.snsinsider.com/reports/non-viral-gene-delivery-technologies-market-8166
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
